Back to Search
Start Over
In vitro studies of deferasirox derivatives as potential organelle-targeting traceable anti-cancer therapeutics
- Source :
- Chem Commun (Camb)
- Publication Year :
- 2021
- Publisher :
- Royal Society of Chemistry (RSC), 2021.
-
Abstract
- We report here strategic functionalization of the FDA approved chelator deferasirox (1) in an effort to produce organelle-targeting iron chelators with enhanced activity against A549 lung cancer cells. Derivative 8 was found to have improved antiproliferative activity relative to 1. Fluorescent cell imaging revealed that compound 8 preferentially localises within the lysosome.
- Subjects :
- Article
Catalysis
03 medical and health sciences
0302 clinical medicine
Fluorescent cell
Lysosome
Organelle
Materials Chemistry
medicine
Lung cancer
030304 developmental biology
0303 health sciences
Chemistry
Deferasirox
Metals and Alloys
Cancer
General Chemistry
medicine.disease
In vitro
Surfaces, Coatings and Films
Electronic, Optical and Magnetic Materials
medicine.anatomical_structure
030220 oncology & carcinogenesis
Ceramics and Composites
Cancer research
medicine.drug
Subjects
Details
- ISSN :
- 1364548X and 13597345
- Volume :
- 57
- Database :
- OpenAIRE
- Journal :
- Chemical Communications
- Accession number :
- edsair.doi.dedup.....0df7c9b600b88aab7080d3090deb97cf